US Market News
3週前
Wellgistics Health Provides Mid-Year 2026 Corporate OutlookJune 1, 2026 7:40 AM
ACCESS NewswireFocus is on closing DelivMeds AI transaction, driving pharmacy revenue growth and supporting PharmacyChain™, Medical Drones and Health Lives Here progressRecent capital raise provides capital into late 2026, including meeting criteria for DelivMeds AI transaction funding closing conditionRecent capital raise and debt restructuring preclude the Company from issuing shares for capital raising purposes until the earlier of seven (7) months from the transaction date and thirty (30) days after effectiveness of the resale registration statement covering the underlying securities.Recent lock-up agreement to limit shares available for sale into the marketExercise of warrants embedded in recent financing would provide funding through 2029 TAMPA, FL / ACCESS Newswire / June 1, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today provided a mid-year 2026 corporate outlook. The Company intends to focus on closing the recently announced DelivMeds AI transaction, continuing to drive quarter-over-quarter growth through its Wellgistics Pharmacy business unit, and supporting the continued progress in the three key aspects of the DelivMeds AI transaction: PharmacyChain™ progress, Medical Drones implementation and Health Lives Here launch scheduled for the third quarter of 2026."The last two weeks have been transformative for the Company from a strategic direction, financial structure and funding standpoint," said Wellgistics Health Interim Co-CEO Gerald Commissiong. "With the reverse split that was required to maintain our NASDAQ listing now behind us, and with the support of holders of a majority of our common shares limiting the supply of common shares available to trade through the lock-up agreement announced last Thursday that leaves approximately 1.3 million shares available to trade based on the Company's current estimates, the Company is now positioned for significant growth in the months ahead. New shares from the financing will not be eligible for resale until they are issued in accordance with the transaction documents and either registered for resale under an effective registration statement or eligible for resale under Rule 144 or another applicable exemption, expected in the third quarter. We expect our previously announced joint venture with KareRx to continue to increase our monthly pharmacy sales and are looking forward to establishing new manufacturer relationships as a result of the DelivMeds AI business model."Mr. Commissiong continued, "With an expeditious closing of the DelivMeds AI transaction squarely in focus, we believe the addition of the ‘all-of-healthcare' smart contracts claims to our exclusive PharmacyChain blockchain intellectual property (IP) stack is poised to significantly expand the Company's relationship with DataVault AI by making it one of Wellgistics' largest shareholders while allowing us to apply the full power of our proprietary EinsteinRx artificial intelligence decision-making technology beyond our current pharmacy-only license. The recently announced QOLPOM IP acquisition, once closed, will allow us to immediately integrate biometric confirmation of a drug's pharmacodynamic effect to begin to objectively confirm prescription use adherence within the Health Lives Here consumer app that is targeted for launch at the 2026 Pro Football Hall of Fame game in Canton, OH in August, while also setting the stage for the coming disruption of the pharmaceuticals and medical supplies delivery sector with biometric confirmation-enabled medical drones.""The Health Lives Here app itself is currently being optimized for that launch, with telemedicine, telelabs and telepharmacy features being added to its unique mental health AI technology in order to tailor coaching and regimen compliance messaging around which the app itself is centered to help patients reach and maintain their health goals," said Mr. Commissiong. "All of these innovations are being built for the launch of Tollo Health's proprietary nutraceutical products starting with Forzet™, a proprietary medical food positioned as an adjunct to GLP-1 agonist drugs to help limit muscle loss. We know that next-generation GLP-1 agonist product candidates in the pipeline are already being positioned to help mitigate muscle loss, and we believe that given Forzet's mechanism of action it will further enhance those drugs' benefit to patients. We also intend to focus on the underserved areas of active viral infections with Galectovid™ and Long COVID with Tollovid™. We believe strongly that the COVID pandemic catalyzed an already-emerging trend of Americans seeking non-pharmaceutical solutions to help improve and maintain healthy immune function, while building muscle. Tollo Health's best-in-breed product pipeline integrated with Wellgistics' pharmacist-led patient-engagement philosophy elevates that message, especially as part of an overall healthcare messaging paradigm being advanced together with NFL Alumni."The anticipated DelivMeds AI and QOLPOM transactions remain subject to the satisfaction or waiver of customary closing conditions and other requirements, and there can be no assurance that either transaction will be completed on the anticipated terms, within the expected timeframe, or at all.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Wellgistics Health recently entered into a fully binding letter of intent with DataVault AI, Inc., EOS Technology Holdings, Inc., Scilex Holdings, Inc. and HealthBridge Advisors LLC to form DelivMeds AI. DelivMeds AI intends to focus on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units to deliver a better healthcare experience for consumers. Tollo Health, the operating company whose control is being contributed to DelivMeds AI by HealthBridge Advisors, has a pending partnership with NFL Alumni Health to advance the Health Lives Here app that will become the centerpiece of DelivMeds AI direct-to-consumer marketing efforts. The transaction is expected to close in the third quarter of 2026.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the Company's financing transaction, the intended use of proceeds, the expected benefits of the refinancing and new capital, the anticipated closing of the previously announced DelivMeds AI Transaction, the satisfaction of closing conditions related thereto, the Company's ability to obtain stockholder approval for the creation of preferred stock, the effectiveness of any registration statement, the automatic exchange or conversion of the New Debt into preferred stock or common stock, the potential conversion of the Funding Preferred into common stock, the Company's growth strategy, operating plans, liquidity position, capital resources, Nasdaq compliance, and the expected benefits of the Company's technology platforms and strategic relationships.Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Company may not complete the DelivMeds AI Transaction on the anticipated terms, or at all; the risk that remaining closing conditions may not be satisfied or waived; the risk that stockholder approval for the creation of preferred stock or related matters may not be obtained; the risk that any required registration statement may not become effective when expected or at all; risks related to the terms, conversion, exchange and potential dilution associated with the New Debt, the Funding Preferred and other securities of the Company; risks related to the Company's ability to successfully integrate, commercialize and scale its business initiatives; risks related to the Company's liquidity, capital resources and ability to fund operations; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence and technology sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Provides Mid-Year 2026 Corporate Outlook
US Market News
4週前
Wellgistics Health Announces Lock-Up Agreement with Holders of a Majority of its Common StockMay 28, 2026 7:40 AM
ACCESS NewswireHolders of 1,333,930 common shares agree to minimum 90-day lock-up agreement TAMPA, FL / ACCESS Newswire / May 28, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that holders of a 1,333,930 common shares, representing a majority of the outstanding common shares of the Company, have entered into a lock-up agreement that precludes the sale of their shares into the market for at least 90 days."This lock-up agreement, when combined with the recent restructuring of our convertible liabilities and the raising of new funding, underscores the confidence our shareholders have in management to execute against our recently-disclosed vertically-integrated growth plan outlined in the Company's recent shareholder letter," said Wellgistics Health Interim Co-CEO Gerald Commissiong. "We believe we will achieve important milestones against our execution plan in the weeks and months ahead. We look forward to updating the market as we make progress in achieving such milestones."About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the Company's recently disclosed growth plan, anticipated milestones, expected market updates, the expected benefits of the lock-up agreement, the Company's shareholder support, management's ability to execute its business strategy, the Company's technology platforms, strategic initiatives, liquidity position, capital resources and Nasdaq compliance.Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, risks related to the Company's ability to execute its growth plan; achieve anticipated milestones; maintain shareholder, investor and market support; obtain, maintain or utilize additional financing; successfully integrate, commercialize and scale its business initiatives and technology platforms; maintain compliance with Nasdaq listing standards; and manage market, regulatory, operational and competitive risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence and technology sectors, as well as other risks described in the Company's filings with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock
US Market News
4週前
Wellgistics Health Refinances Outstanding Convertible Debt and Raises $6.5MMay 27, 2026 5:50 PM
ACCESS NewswireNew oversubscribed $21 million convertible debt instrument ("New Debt") refinances all outstanding convertible debt, provides $6.5 million in new capital for working capital and general corporate purposes does not accrue interest and converts into common shares at $6.00 per shareAutomatic Exchange provision automatically converts the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred StockThe class of Preferred Stock that the New Convertible Debt exchanges into (the "Funding Preferred") converts into common shares at $50.00 per shareNew funds raised satisfy capital raising closing condition from Fully Binding Term Sheet with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors TAMPA, FL / ACCESS Newswire / May 27, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a Health IT leader, integrating pharmacy dispensing AI platform EinsteinRx™ into patented pharmacy smart contracts platform PharmacyChain™, today announced that it completed a financing transaction through the issuance of a new $21 million convertible debt instrument (the "New Debt") that refinances all of its outstanding convertible debt and provides $6.5 million in fresh capital (the "New Money"). The offering was oversubscribed. The New Money raised in this transaction satisfies the capital raising closing condition outlined in the previously announced fully binding term sheet the Company entered into with Datavault AI, EOS Technology Holdings, Scilex Pharma and HealthBridge Advisors (the "DelivMeds AI Transaction"). Dawson James Securities, Inc. acted as placement agent for the financing."This transaction refinanced all of the Company's previously outstanding convertible debt and raised the new capital necessary to close the DelivMeds AI Transaction," said Gerald Commissiong, Interim Co-CEO of Wellgistics Health. "We are grateful for the strong vote of confidence from the pre-existing and new investors who participated in this funding round. We believe we now have a strong operational mandate and the capital needed to execute our vertically-integrated growth strategy."Under the terms of the agreements, New Debt was issued that refinanced all outstanding convertible debt of the Company, provided $6.5 million in new capital for go-forward operations, does not accrue interest and converts into common shares at $6.00 per share. The terms of the New Debt have a provision that automatically forces the exchange of the New Debt into Preferred Stock upon the effectiveness of a registration statement and attainment of shareholder approval for the creation of Preferred Stock. The creation of Preferred Stock is a requirement of the DelivMeds AI Transaction. The class of Preferred Stock that the New Debt will be forced to exchange into (the "Funding Preferred") converts into common shares at $50.00 per share.The stated conversion price of the Funding Preferred does not reflect the current market price of the Company's common stock, and there can be no assurance that the Company's common stock will trade at or above such price. All conversion prices are subject to adjustments for market conditions. Additional information regarding the transaction, including copies or summaries of the definitive agreements, will be included in a Current Report on Form 8-K filed with the Securities and Exchange Commission.The transaction may result in substantial future dilution to existing stockholders upon conversion of the securities described above.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a Health IT leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.For more information, visit www.wellgisticshealth.com.Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding the Company's financing transaction, the intended use of proceeds, the expected benefits of the refinancing and new capital, the anticipated closing of the previously announced DelivMeds AI Transaction, the satisfaction of closing conditions related thereto, the Company's ability to obtain stockholder approval for the creation of preferred stock, the effectiveness of any registration statement, the automatic exchange or conversion of the New Debt into preferred stock or common stock, the potential conversion of the Funding Preferred into common stock, the Company's growth strategy, operating plans, liquidity position, capital resources, Nasdaq compliance, and the expected benefits of the Company's technology platforms and strategic relationships.Forward-looking statements are based on current expectations, estimates, projections and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, among others, the risk that the Company may not complete the DelivMeds AI Transaction on the anticipated terms, or at all; the risk that remaining closing conditions may not be satisfied or waived; the risk that stockholder approval for the creation of preferred stock or related matters may not be obtained; the risk that any required registration statement may not become effective when expected or at all; risks related to the terms, conversion, exchange and potential dilution associated with the New Debt, the Funding Preferred and other securities of the Company; risks related to the Company's ability to successfully integrate, commercialize and scale its business initiatives; risks related to the Company's liquidity, capital resources and ability to fund operations; risks related to maintaining compliance with Nasdaq listing standards; market, regulatory and operational risks affecting the healthcare, pharmacy, pharmaceutical distribution, artificial intelligence and technology sectors; and other risks described in the Company's filings with the Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Refinances Outstanding Convertible Debt and Raises $6.5M
US Market News
1月前
CORRECTION FROM SOURCE: Wellgistics Health Releases Letter to Our ShareholdersMay 21, 2026 10:50 AM
ACCESS NewswireThis Press Release updates the information from the previous release.Why Vertical Integration and Blockchain Will Define the Next Era of HealthcareTAMPA, FL / ACCESS Newswire / May 21, 2026 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today released a letter to shareholders expanding upon the strategy behind recently announced transactions.'Dear Fellow Shareholders,Yesterday we announced a series of transactions that, taken together, mark the most consequential strategic moment in Wellgistics Health's history. We are writing today to explain what connects them - and why we believe the steps we are taking now will position Wellgistics as essential infrastructure for the healthcare industry of the next decade.Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale. Every participant in healthcare - providers, payors, pharmacies, manufacturers, and patients - is operating with fragmented data, duplicated workflows, and trust gaps that cost the system hundreds of billions of dollars each year. We believe these inefficiencies cannot be solved by another point solution layered on top of legacy systems. They require a unified data fabric that captures, verifies, and exchanges health information across every node of care. That fabric will be built on blockchain. We believe it is not a question of whether the industry adopts blockchain-based infrastructure, but when - and who is positioned to provide it.That conviction is the strategic logic behind every announcement we made yesterday.DelivMeds AI and the expanded Datavault license give us the enabling intellectual property for commercial tokenized healthcare data management. Tokenization is the mechanism that turns fragmented health data into a verifiable, exchangeable, and valuable asset. By forming DelivMeds AI and consolidating these capabilities inside our EinsteinRx™ platform, we are building the data layer that the rest of the industry will eventually need to plug into.The QOLPOM patent portfolio brings remote biometric patient verification, technology-enabled pharmacodynamic monitoring, and medical drone biometric IP under our roof. Verification is the foundation of trust in any tokenized data system. Without it, health data cannot be reliably exchanged or monetized. QOLPOM's IP gives us the authentication layer that makes the data layer credible. And it opens up a potential unique future last-mile solution using drones capable of biometric patient verification to deliver prescriptions and pickup diagnostic specimen collection for lab services in rural communities.The Tollo Health controlling interest and Forzet™ extend our reach directly to the patient. Through the Health Lives Here program in partnership with NFL Alumni Health, we will engage GLP-1 patients managing muscle loss - generating real-world adherence, outcomes, and biometric data that flows back into our platform. This is vertical integration in practice: from the manufacturer relationship, through the pharmacy network, the prescription dispensing event, the patient's daily experience, and back into the data infrastructure that improves the next decision.Each of these moves stands on its own. Together, they form a single integrated thesis. The pharmacy is the most under-appreciated touchpoint in healthcare - it is where prescriptions are filled, where adherence begins, and where the richest longitudinal data on patient behavior already lives. We have spent years building the connective tissue across 6,500 pharmacies and 200+ manufacturers. We are now extending that connective tissue upstream into data infrastructure and downstream into patient care.The companies that will define healthcare over the next ten years will not be the ones with the best single product. They will be the ones who own the data, the verification, and the patient relationship - and who can move information across all three with cryptographic trust. That is what we are building.We recognize that the breadth of yesterday's announcements raises questions, and we are committed to keeping our shareholders informed at every step. We will provide additional detail in the coming weeks as definitive agreements are finalized.The planned share restructuring and new CUSIP support the Company's next phase of growth.Thank you for your continued confidence in Wellgistics Health. We are building this Company with conviction, and we believe the foundation we are laying now will deliver durable value for shareholders, providers, and patients alike.'Sincerely,Gerald Commissiong
Interim Co-Chief Executive OfficerPrashant Patel
Interim Co-Chief Executive OfficerAbout Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August 2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding GLP-1 related opportunities, the integration of PharmacyChain™ functionality with EinsteinRx™, the potential expansion of the Datavault AI PharmacyChain™ license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant data transfer functionality, the potential acquisition of the QOLPOM IP portfolio, the potential acquisition of a controlling interest in Tollo Health, LLC, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "may," "will," "would," "could," "should," "seek," "estimate," "project," "potential," "continue" and similar expressions.Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain™ functionality and other strategic initiatives; the Company's ability to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize and scale EinsteinRx™ and PharmacyChain™-enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare, FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings; the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: CORRECTION FROM SOURCE: Wellgistics Health Releases Letter to Our Shareholders
US Market News
1月前
Wellgistics Health Releases Letter to Our ShareholdersMay 21, 2026 9:35 AM
ACCESS NewswireWhy Vertical Integration and Blockchain Will Define the Next Era of HealthcarePHILADELPHIA, PA / ACCESS Newswire / May 21, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company"), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA') tokenization technologies, today entered into a fully binding term sheet (the "Binding Term Sheet") with Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today released a letter to shareholders expanding upon strategy behind recently announced transactions.'Dear Fellow Shareholders,Yesterday we announced a series of transactions that, taken together, mark the most consequential strategic moment in Wellgistics Health's history. We are writing today to explain what connects them - and why we believe the steps we are taking now will position Wellgistics as essential infrastructure for the healthcare industry of the next decade.Our thesis is straightforward: vertical integration is the only path to real efficiency in healthcare, and blockchain is the only architecture capable of supporting it at scale. Every participant in healthcare - providers, payors, pharmacies, manufacturers, and patients - is operating with fragmented data, duplicated workflows, and trust gaps that cost the system hundreds of billions of dollars each year. We believe these inefficiencies cannot be solved by another point solution layered on top of legacy systems. They require a unified data fabric that captures, verifies, and exchanges health information across every node of care. That fabric will be built on blockchain. We believe it is not a question of whether the industry adopts blockchain-based infrastructure, but when - and who is positioned to provide it.That conviction is the strategic logic behind every announcement we made yesterday.DelivMeds AI and the expanded Datavault license give us the enabling intellectual property for commercial tokenized healthcare data management. Tokenization is the mechanism that turns fragmented health data into a verifiable, exchangeable, and valuable asset. By forming DelivMeds AI and consolidating these capabilities inside our EinsteinRx™ platform, we are building the data layer that the rest of the industry will eventually need to plug into.The QOLPOM patent portfolio brings remote biometric patient verification, technology-enabled pharmacodynamic monitoring, and medical drone biometric IP under our roof. Verification is the foundation of trust in any tokenized data system. Without it, health data cannot be reliably exchanged or monetized. QOLPOM's IP gives us the authentication layer that makes the data layer credible. And it opens up a potential unique future last-mile solution using drones capable of biometric patient verification to deliver prescriptions and pickup diagnostic specimen collection for lab services in rural communities.The Tollo Health controlling interest and Forzet™ extend our reach directly to the patient. Through the Health Lives Here program in partnership with NFL Alumni Health, we will engage GLP-1 patients managing muscle loss - generating real-world adherence, outcomes, and biometric data that flows back into our platform. This is vertical integration in practice: from the manufacturer relationship, through the pharmacy network, the prescription dispensing event, the patient's daily experience, and back into the data infrastructure that improves the next decision.Each of these moves stands on its own. Together, they form a single integrated thesis. The pharmacy is the most under-appreciated touchpoint in healthcare - it is where prescriptions are filled, where adherence begins, and where the richest longitudinal data on patient behavior already lives. We have spent years building the connective tissue across 6,500 pharmacies and 200+ manufacturers. We are now extending that connective tissue upstream into data infrastructure and downstream into patient care.The companies that will define healthcare over the next ten years will not be the ones with the best single product. They will be the ones who own the data, the verification, and the patient relationship - and who can move information across all three with cryptographic trust. That is what we are building.We recognize that the breadth of yesterday's announcements raises questions, and we are committed to keeping our shareholders informed at every step. We will provide additional detail in the coming weeks as definitive agreements are finalized.The planned share restructuring and new CUSIP support the Company's next phase of growth.Thank you for your continued confidence in Wellgistics Health. We are building this Company with conviction, and we believe the foundation we are laying now will deliver durable value for shareholders, providers, and patients alike.'Sincerely,Gerald Commissiong
Interim Co-Chief Executive OfficerPrashant Patel
Interim Co-Chief Executive OfficerForward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August 2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding GLP-1 related opportunities, the integration of PharmacyChain™ functionality with EinsteinRx™, the potential expansion of the Datavault AI PharmacyChain™ license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant data transfer functionality, the potential acquisition of the QOLPOM IP portfolio, the potential acquisition of a controlling interest in Tollo Health, LLC, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "may," "will," "would," "could," "should," "seek," "estimate," "project," "potential," "continue" and similar expressions.Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain™ functionality and other strategic initiatives; the Company's ability to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize and scale EinsteinRx™ and PharmacyChain™-enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare, FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings; the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Releases Letter to Our Shareholders
US Market News
1月前
Wellgistics Health Announces Reverse Stock SplitMay 20, 2026 6:00 PM
ACCESS NewswireTAMPA, FL / ACCESS Newswire / May 20, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its board of directors approved the Company's 1-for-50 reverse stock split (the "Reverse Split") of the Company's common stock, par value $0.00001 per share (the "Common Stock"). The Reverse Split was approved by a majority of the stockholders of the Company on April 2, 2026. Post-split, the common stock security will trade under a new CUSIP number.The Reverse Split will legally take effect at 12:01 a.m. Eastern Time, on May 26, 2026. The Reverse Split is intended to increase the per share trading price of the Common Stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.The 1-for-50 Reverse Split will automatically convert every 50 current shares of the Company's Common Stock into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Split. Any fractional share of Common Stock that would otherwise result from the Reverse Split will be rounded up to the nearest whole share.The Reverse Split will reduce the number of shares of outstanding Common Stock from approximately 125,671,251 to approximately 2,513,425 shares of Common Stock. The total authorized number of shares will not be reduced. Proportional adjustments will also be made to the exercise and conversion prices of the Company's outstanding stock options, warrants, and convertible securities, and to the number of shares issued and issuable under the Company's stock incentive plans.Stockholders holding their shares electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares through a bank, broker, or other nominee will have their positions automatically adjusted to reflect the Reverse Split, subject to brokers' particular processes, and will not be required to take any action in connection with the Reverse Split.Additional information regarding the Reverse Split is available in the Company's definitive information statement originally filed with the U.S. Securities and Exchange Commission (SEC) on April 3, 2026.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Announces Reverse Stock Split
US Market News
1月前
Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo HealthMay 20, 2026 9:11 AM
Business Wire Formation of DelivMeds AI, Inc. (ticker reserved: NASDAQ:MEDS), with an expected approximate combined asset value of $4 billion, is subject to an independent fairness opinion. Fully binding term sheet between Datavault AI (NASDAQ:DVLT) and Wellgistics Health (NASDAQ:WGRX) expands PharmacyChain™ to Healthcare-as-a-Service (“HaaS”) IP, connecting DelivMeds AI to Wellgistics’ 6,500+ pharmacies and 200+ manufacturers, uniting blockchain-enabled healthcare data management & pharmaceuticals delivery QOLPOM patent portfolio acquisition adds technology-enabled biometric verification of pharmacodynamic response intellectual property, AI-enabled medical drones for diagnostic sample collection and pharmacy delivery with biometric patient verification at the point of delivery, vastly improving the connection between rural communities and their local pharmacies Acquisition of controlling stake in Tollo Health pharmaceuticals adjacent GLP-1 muscle loss and acute viral infection medical foods, and chronic viral infection-focused supplement portfolio and its AI-driven coaching and regimen compliance ‘Health Lives Here’ consumer health app in partnership with NFL Alumni Health (“NFL-AH”) developed to support the launch of Forzet™ as a medical food to help mitigate the muscle loss from weight loss therapies that was recently featured with NFL-AH during the 2026 NFL Draft in Pittsburgh Pilot ‘Health Lives Here’ rollout target to begin in North Carolina in July 2026 in preparation for August 2026 Pro Football Hall of Fame Game Forzet-centered official launch Gerald Commissiong appointed Interim Co-CEO of Wellgistics Health Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a provider of data monetization, credentialing, digital engagement, and real-world asset (‘RWA’) tokenization technologies, today entered into a fully binding term sheet (the “Binding Term Sheet”) with Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, to build Wellgistics into DelivMeds AI, a healthcare company that will focus on improving data driven outcomes following the completion of three concurrent transactions: 1) the expansion of Datavault AI’s previously disclosed PharmacyChain™ license (“License”) to include Healthcare-as-a-Service (“HaaS”)-related intellectual property; 2) the acquisition of the QOLPOM intellectual property from EOS Technology Holdings, Inc. (EOS Holdings) and Scilex Holding Company (“Scilex”) (NASDAQ:SCLX) that enables wearables-driven biometric confirmation of pharmacodynamic drug effect and biometric confirmation named-patient to receive home drug delivery; and 3) the acquisition of a controlling stake in Tollo Health, LLC which manufactures unique medical foods and dietary supplements for GLP-1 muscle loss, acute viral infections and chronic viral infection syndromes, proprietary consumer engagement technology, and proprietary marketing channels. Gerald Commissiong has concurrently been appointed Interim Co-CEO of Wellgistics. Together, the three transactions forming DelivMeds carry an expected approximate combined asset value of $4 billion, subject to an independent fairness opinion. “There is a tremendous opportunity to transition this highly valuable portfolio of assets into a robust business centered on quantifying and improving patient outcomes using DelivMeds’ unique access to a proprietary healthcare data stack,” said Gerald Commissiong, Interim Co-CEO of Wellgistics Health. “By combining proprietary pharmaceutical-adjunct nutraceutical solutions with AI-personalized behavioral health technology into patient engagement workflows, we have a unique approach to drive digital health adoption and improve compliance.” DelivMeds AI will bring national pharmacy scale to “Health Lives Here”, the consumer health program that was featured by NFL Alumni Health (NFL-AH) and Tollo Health during NFL Draft Week in Pittsburgh in April 2026. Health Lives Here’s national rollout through the Wellgistics Pharmacy Network will pilot in North Carolina beginning in July 2026, leading up to the formal launch as part of 2026 Pro Football Hall of Fame Game NFL-AH activities in August. “DelivMeds AI brings together the infrastructure we have been building - blockchain-enabled pharmacy delivery, AI-driven logistics, and biometric verification - into a single direct-to-consumer platform that serves patients where they live. This is data infrastructure meeting real-world healthcare delivery at scale,” said Nathaniel T. Bradley, CEO of Datavault AI. Expansion of PharmacyChain™ license to include Healthcare-as-a-Service (HaaS) The pharmacy infrastructure of DelivMeds AI is anchored by the PharmacyChain™ License, expanded to include Healthcare-as-a-Service (HaaS)-related intellectual property, giving the platform reach across the complete prescription drug dispensing process through Wellgistics Pharmacy Network’s more than 6,500 pharmacies and 200+ manufacturers. Wellgistics’ proprietary EinsteinRx™ AI handles eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment at scale, while PharmacyChain™ provides the underlying blockchain-enabled smart contracts infrastructure. According to SNS Insider, the U.S. blockchain in healthcare market was valued at $7.13 billion in 2023 and is projected to reach $595.31 billion by 2032, at a compounded annual growth rate (CAGR) of 63.5%. See Datavault AI’s November 25, 2025 PharmacyChain™ license announcement. Quality of Life Peace of Mind (QOLPOM™) Intellectual Property Acquisition The QOLPOM patent portfolio acquired from EOS Technology Holdings, Inc. and Scilex Holding Company (NASDAQ:SCLX) extends DelivMeds AI’s reach beyond the pharmacy counter. The IP combines wearables-enabled biometric pharmacodynamic drug effect confirmation and biometric confirmation for named-patient delivery by Data Driven Drones™ delivering medical supplies, diagnostic sample collection kits and biopharmaceutical drugs that will substantially improve last-mile fulfillment and sample collection in rural America and other underserved markets. The QOLPOM technology’s contactless identity confirmation addresses a compliance and fraud-prevention gap critical to pharmaceutical distribution. According to Market Research Future, the global drone-enabled medical supplies pickup and delivery market was valued at $430 million in 2023 and is projected to reach $2.49 billion by 2032, at a CAGR of 21.20%. Acquisition of controlling interest in Tollo Health The clinical layer of DelivMeds AI is built through the acquisition of a controlling stake in Tollo Health, LLC. Tollo adds telemedicine and AI-enabled mental health coaching and regimen compliance management, along with a portfolio of proprietary medical foods and dietary supplements targeting three fast-growing indications: 1) Weight loss therapy-associated muscle loss, 2) Long COVID and 3) Acute viral infections. The NFL Alumni Health marketing partnership will connect DelivMeds AI directly to patients managing chronic pain, orthopedic injury, and muscle-loss side effects that accompany GLP-1 agonist use and provides national brand reach tied to the “Health Lives Here” August launch. According to Grand View Research, the GLP-1 receptor agonist market is expected to grow from $66 billion in 2025 to $185 billion in 2033, at a CAGR of 12.4%, with skeletal muscle loss documented as a key side effect of GLP-1 therapies and a primary target indication for Tollo Health’s proprietary supplement portfolio. The consummation of the transactions contemplated by the Binding Term Sheet remains subject to customary due diligence, a fairness opinion, execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. About Datavault AI Datavault AI™ (NASDAQ:DVLT) is leading the way in AI-driven data experiences, valuation, and monetization of assets in the Web 3.0 environment. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Sciences and Data Sciences divisions. Datavault AI's Acoustic Sciences division features WiSA®, ADIO®, and Sumerian® patented technologies and industry-first foundational spatial and multichannel wireless, high-definition sound transmission technologies with intellectual property covering audio timing, synchronization, and multi-channel interference cancellation. The Data Science division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation, and secure monetization. Datavault AI's platform serves multiple industries, including high-performance computing software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy, and more. The Information Data Exchange® enables Digital Twins and the licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata, fostering responsible AI with integrity. The Company's technology suite is fully customizable and offers AI- and machine-learning-based automation, third-party integration, detailed analytics and data, marketing automation, and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai. About Wellgistics Health, Inc. Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem. About Tollo Health, LLC Tollo Health, LLC is a medical foods and precision nutraceutical company seeking to bring to market proprietary formulations for the dietary management of GLP-1 treatment-related side effects and chronic viral conditions, including Long COVID. Tollo intends to bring to market a full suite of products that provide patients with prescription medication-enabling benefits in areas with approved drugs and functional relief in conditions for which there are no approved drugs, but mechanistic understanding of the disease is improving. By using tailored natural product formulation that deliver the cGMP-manufactured ingredients with the right formulation at the right dose, Tollo aims to fill a key gap in the delivery of prescription drugs that have side effects and chronic conditions for which there are no approved treatments. For more information, please visit Tollo’s website at www.tollohealth.com. About Scilex Holding Company Scilex is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur Pharmaceuticals, Inc. (“Semnur”) (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia. Scilex is headquartered in Palo Alto, California. Forward-Looking Statements This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding: the anticipated conversion of the Binding Term Sheet with Wellgistics Health, Inc. into definitive agreements; the planned expansion of the PharmacyChain™ license scope to cover all healthcare as a service (HaaS)-related intellectual property; the planned formation, launch, and commercial development of DelivMeds AI, Inc. and its proposed listing on NASDAQ under the ticker symbol MEDS; the anticipated acquisition of QOLPOM patents from EOS Technology Holdings, Inc. and Scilex Holding Company (NASDAQ:SCLX) and the expected contribution of biometric verification and AI drone-enabled medical delivery capabilities; the anticipated acquisition of a controlling stake in Tollo Health, LLC and the expected addition of telemedicine, mental health coaching, and proprietary medical food and dietary supplement products; the expected approximate combined asset value of $4 billion of DelivMeds AI; the planned national rollout of the “Health Lives Here” program through the DelivMeds AI pharmacy network beginning around the 2026 Pro Football Hall of Fame Game; and the expected operational, technical, and commercial outcomes of these transactions and Datavault AI’s commercial strategy, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks that the Binding Term Sheet may not convert to definitive agreements due to the failure to complete required due diligence, obtain a satisfactory fairness opinion, receive board approvals, or secure necessary financing; risks that the independent fairness opinion with respect to the expected approximate asset value of $4 billion may not support such valuation or may result in material adjustments to the terms of the transactions; risks associated with the integration of acquired intellectual property, businesses, and technologies, including QOLPOM patents and Tollo Health; regulatory risks applicable to pharmaceutical distribution, AI drone-enabled medical delivery (including FAA and FDA oversight), and digital health applications; commercial risks associated with the launch and adoption of a new direct-to-consumer health application; risks that the QOLPOM patent acquisition or Tollo Health controlling-stake acquisition may not close on the anticipated terms or timeline; reimbursement and commercialization risks for pharmaceutical and medical supply delivery services; changes in market demand for Datavault AI’s services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets and blockchain-enabled healthcare commerce; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, or investments it may make. Industry and Market Data Within this press release, we reference information and statistics regarding the markets for healthcare blockchain technology, medical drone delivery, and GLP-1 receptor agonists. We have obtained this information from various independent third-party sources, including independent industry publications and reports by market research firms. Some data and other information contained in this press release are also based on management’s estimates and calculations, which are derived from our review and interpretation of internal surveys and independent sources. While we believe such information is reliable, we have not independently verified any third-party information. While we believe our internal company research and estimates are reliable, such research and estimates have not been verified by any independent source. In addition, assumptions and estimates of our and our industry’s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause our future performance to differ materially from our assumptions and estimates. As a result, you should be aware that market, ranking, and other similar industry data included in this press release, and estimates and beliefs based on that data, may not be reliable. Trademarks, Trade Names, Service Marks, and Copyrights We own or have rights to use various trademarks, tradenames, service marks, and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks, and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the ©, ®, and ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties’ trademarks, tradenames, service marks, or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties. View source version on businesswire.com: https://www.businesswire.com/news/home/20260520800818/en/ Media Contact:
marketing@dvlt.ai Investor Contact:
Edward Barger
VP, Investor Relations
ebarger@dvlt.ai | ir@dvlt.ai Wellgistics Media Contact:
media@wellgisticshealth.com Wellgistics Investor Relations Contact:
IR@wellgisticshealth.com Original: Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health
US Market News
1月前
Wellgistics Health Reports First Quarter 2026 Financials and Provides Business UpdateMay 19, 2026 4:10 PM
ACCESS NewswireWellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited resultsQ1-26 focus on optimization of Wellgistics Pharmacy revenue growth and capabilities positions Company to integrate emerging licensed PharmacyChain™ pharmacy data tokenization technology into pharmacy dispensing AI hub EinsteinRx™Kare Pharmtech joint venture expands the Company's telepharmacy and direct-to-patient capabilities, providing immediate access to 200,000+ patient livesStrategic partnership with Tollo Health provides access to proprietary pharmaceutical-adjunct medical foods & dietary supplements, telemedicine and mental health AI coaching & regimen compliance tools via "Health Lives Here" app that is targeted to launch in August 2026 following the reveal with NFL Alumni Health at 2026 NFL Draft in PittsburghThe Company is in advanced discussions with Datavault AI regarding a binding term sheet to expand the scope of the PharmacyChain™ license to include Health-as-a-Service (HaaS) capabilitiesCompany has terminated previously announced non-binding letters of intent with Neuritek and WellCare and does not intend to proceed with those transactions TAMPA, FL / ACCESS Newswire / May 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology company, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ with licensed blockchain-enabled smart contract technology through PharmacyChain™, reported financial results for the first quarter ended March 31, 2026 and provided a second quarter 2026 business update from its President & Interim-CEO Prashant Patel, RPh."The Company's first quarter focus on expanding direct sales from its Wellgistics Pharmacy segment led to sequential quarter over quarter growth that is now beginning to reach critical mass in the second quarter," said Prashant Patel, RPh, President & Interim-CEO Prashant Patel. "We believe the sequential growth in Wellgistics Pharmacy revenue, together with our Kare Pharmtech joint venture, provides a foundation for continued expansion of our direct-to-patient initiatives. As we work to onboard patient lives available through the joint venture and prepare for the targeted August 2026 launch of the Health Lives Here initiative with Tollo Health and NFL Alumni Health, we are also continuing to advance the integration of PharmacyChain™ functionality with our EinsteinRx™ pharmacy dispensing AI hub. As we onboard an increasing percentage of the 200,000+ patient lives through the joint venture, we are preparing to support a significant ramp up in prescription dispending through our direct-to-consumer initiatives with Tollo Health coming from that planned August 2026 launch through the partnership with NFL Alumni Health of the "Health Lives Here initiative" that was revealed at the 2026 NFL Draft in Pittsburgh."Mr. Patel continued, "As we engage with stakeholders in the pharmaceutical distribution space, we believe the GLP-1 market remains in an early stage of development and that products such as the Forzet™ medical food product, which is intended to support the dietary management of muscle loss associated with weight-loss therapies may represent an important adjunct opportunity," We intend to increasingly focus on the GLP-1 segment and consolidate the capabilities required to provide what we believe to be a seamless end-to-end user experience that will likely lead to strong customer satisfaction and retention.""We believe the cost reduction and operating discipline implemented by management have better aligned the Company's expense structure with its near-term revenue opportunities," noted Mr. Patel.First Quarter 2026 Corporate HighlightsSequential quarter over quarter revenue growth:Q4-2025: $0.486 millionQ1-2026: $0.929 millionQ2-2026: The Company expects revenue of $1.775 million (projected, $0.86M already recognized through May 18, 2026)Added quantum key encryption functionality to the Datavault AI PharmacyChain™ license to enhance security features for the Company's emerging pharmaceutical distribution-focused blockchain platform Tollo Health partnership expansion adds telehealth, mental health AI coaching & regimen compliance tools via proprietary app, proprietary medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies, and NFL Alumni Health's "Health Lives Here" marketing partnership to Wellgistics capabilitiesInsurance Eligibility and benefits verification (EBV) services added to EinsteinRx offeringContinued strategic shift focusing on direct-to-consumer marketSecond Quarter 2026 Corporate Highlights to Date and Upcoming MilestonesProgress to dateCompleted joint venture with KareRx to add KareRx technology hub and operations to EinsteinEx, gaining telepharmacy capabilities and operations in order to position for increasing Wellgistics Pharmacy dispensing activities, onboarding of new manufacturer relationships and execution of the pending "Health Lives Here" app launch targeted for August 2026 in partnership with NFL Alumni HealthPending milestonesContinue discussions with Datavault AI regarding an expansion of the PharmacyChain™ license to include Health-as-a-Service capabilities Establish initial HIPAA-compliant data transfer functionality designed to support smart contract-enabled prescription drug transactions through Wellgistics PharmacyLoss from Operations:The Company recorded a net operating loss of $7.742 million in the quarter ended March 30, 2026 compared with a net operating loss of $32.430 million for the quarter ended March 31, 2025. The decrease was largely due to a decrease in general and administrative expenses resulting from the implementation of cost cutting and other strategic measures by new management. Net operating loss per share for the quarter ended March 31, 2026 was $0.07 on 104.6 million weighted average shares outstanding compared to the quarter ended March 31, 2025 where the Company delivered a loss of $0.62 per share on 51.916 million weighted average shares outstanding.This press release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX), is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company's expected second quarter 2026 revenue, expected growth of Wellgistics Pharmacy revenue, the anticipated benefits of the Kare Pharmtech joint venture, the anticipated onboarding of patient lives, the targeted August 2026 launch of the Health Lives Here app, the anticipated benefits of the Tollo Health partnership, the Company's plans regarding GLP-1 related opportunities, the integration of PharmacyChain™ functionality with EinsteinRx™, the potential expansion of the Datavault AI PharmacyChain™ license to include Health-as-a-Service capabilities, the expected development of HIPAA-compliant data transfer functionality, and the Company's expectations regarding its business strategy, operating discipline, revenue opportunities and future growth. Forward-looking statements are based on current expectations, estimates, forecasts and projections and are not guarantees of future performance. These statements may be identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "may," "will," "would," "could," "should," "seek," "estimate," "project," "potential," "continue" and similar expressions.Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied, including, among others: the Company's ability to achieve expected revenue growth; the risk that preliminary second quarter results may differ from actual results following quarter-end close procedures; the Company's ability to successfully integrate Kare Pharmtech, Tollo Health, Datavault AI PharmacyChain™ functionality and other strategic initiatives; the Company's ability to launch the Health Lives Here app on the anticipated timeline or at all; the Company's ability to successfully develop, commercialize and scale EinsteinRx™ and PharmacyChain™-enabled capabilities; regulatory, reimbursement, data privacy, HIPAA, healthcare, FDA, FTC and other compliance risks; risks associated with medical food, dietary supplement, telehealth and AI-enabled healthcare offerings; the Company's ability to maintain and expand manufacturer, pharmacy, patient and strategic partner relationships; competitive conditions in the healthcare technology, pharmacy, telehealth and pharmaceutical distribution markets; the availability of capital; the Company's ability to maintain compliance with Nasdaq listing requirements; and the other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections of the Company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update
US Market News
1月前
Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026May 15, 2026 4:01 PM
ACCESS NewswireTAMPA, FL / ACCESS Newswire / May 15, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026
US Market News
1月前
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring ProgramMay 14, 2026 3:05 PM
ACCESS NewswireHighlights:WellCare Today brings established RPM, RTM and CCM infrastructure with wearable technology integrations and connected monitoring solutionsCombination expected to integrate Wellgistics Health recently announced MSO initiative with Kare Clinicals and its network of 6,500+ independent pharmaciesProposed platform designed to enhance patient engagement, medication adherence, remote monitoring and longitudinal care coordinationProposed transaction valued at approximately $15 millionStrategic initiative intended to create additional clinical revenue opportunities for participating pharmacies and providers TAMPA, FL / ACCESS Newswire / May 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it has executed a non-binding letter of intent ("LOI") to acquire WellCare Today. The proposed transaction structure includes a structured cash payment of $3 million, with the balance to be satisfied through a performance-based earnout issued in preferred stock.WellCare Today is a healthcare technology and remote monitoring company focused on chronic care management ("CCM"), remote patient monitoring ("RPM"), and remote therapeutic monitoring ("RTM") programs. The company delivers HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its broader Health Monitoring & Emergency Support Ecosystem. The platform enables passive, continuous monitoring of key health metrics including heart rate, blood oxygen levels, temperature, sleep patterns, activity tracking, and self-reported medication adherence through Medicare-reimbursable RPM and RTM programs. No assurance can be given that any particular patient, provider, pharmacy, service, device or workflow will qualify for reimbursement.Under the proposed transaction structure, Wellgistics Health intends to integrate WellCare Today's HealthAssist® platform and RPM, RTM and CCM capabilities with the Company's recently announced MSO pilot collaboration involving Kare Clinicals, a division of Kare PharmTech, LLC, as well as its network of more than 6,500 independent pharmacies. The combined infrastructure is intended to support scalable patient engagement, medication adherence initiatives, longitudinal monitoring programs, chronic disease management, and enhanced care coordination workflows across provider and pharmacy channels utilizing connected wearable technologies and remote monitoring infrastructure.The proposed transaction is also expected to create opportunities for participating pharmacies within the Wellgistics Pharmacy Network to engage in clinical service programs associated with RPM, RTM and CCM initiatives, while enabling providers to access scalable care coordination, monitoring, and reimbursement infrastructure. The companies believe the proposed collaboration may establish a more connected healthcare ecosystem aligning patients, pharmacies, providers, wearable technologies, and longitudinal care coordination services through technology-enabled engagement and remote monitoring platforms.The LOI is non-binding, and completion of the proposed transaction remains subject to customary due diligence, negotiation and execution of definitive agreements, board approvals, financing considerations, and other customary closing conditions. There can be no assurance that a definitive agreement will be executed or that the proposed transaction will be completed as currently contemplated, or at all.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects more than 6,500 pharmacies and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility verification, onboarding, adherence support, prior authorization, and cash-pay fulfillment designed to improve patient access and transparency across the prescription ecosystem.About WellCare Today, LLCWellCare Today is a healthcare technology company delivering HealthAssist®, an advanced remote health monitoring platform embedded within standalone Samsung Galaxy Watch devices as part of its comprehensive Health Monitoring & Emergency Support Ecosystem. HealthAssist® enables passive, continuous monitoring of key health metrics including hourly heart rate, hourly blood oxygen levels, temperature, daily steps, sleep patterns, and self-reported medication adherence. Integrated with Remote Therapeutic Monitoring (RTM) and Remote Patient Monitoring (RPM) programs reimbursable by Medicare, HealthAssist® delivers an affordable, scalable solution designed to support seniors and individuals managing chronic health conditions.All RPM, RTM, CCM and related care-coordination services are expected to be furnished, supervised, documented and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, and professional practice rules. The Company does not provide medical advice through this press release, and participation in any program will be subject to applicable clinical, contractual, regulatory and reimbursement requirements.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. Forward-looking statements include, without limitation, statements regarding the proposed acquisition of WellCare Today, LLC; the anticipated structure, valuation, consideration, preferred-stock terms and potential timing of any transaction; the Company's ability to complete due diligence, negotiate and enter into definitive agreements, obtain board approvals, secure financing, satisfy closing conditions and complete the proposed transaction; the potential integration of WellCare Today's platform, technology, personnel, programs and workflows with the Company's MSO, pharmacy network, provider and healthcare technology initiatives; the potential use of HealthAssist® and connected wearable technologies in RPM, RTM, CCM, medication adherence, patient engagement and care-coordination programs; the potential participation of pharmacies, providers, patients and payors; the potential availability of reimbursement for RPM, RTM, CCM or related services; the potential creation of revenue opportunities; and the Company's growth strategy, business plans and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will" and similar expressions. These statements are based on current expectations, assumptions and estimates and are subject to risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; the risk that the proposed valuation, consideration, preferred-stock terms or other transaction terms change materially; the risk that required financing, board approvals, third-party approvals or regulatory approvals are not obtained on acceptable terms or at all; the risk that Nasdaq shareholder approval or other Nasdaq requirements may apply depending on the final transaction terms; the risk that acquired technologies, programs or operations are not successfully integrated; the risk that anticipated benefits, synergies, provider adoption, pharmacy participation, patient engagement, reimbursement or revenue opportunities are not realized; risks associated with healthcare regulation, Medicare and payor requirements, fraud and abuse laws, privacy and data-security requirements, professional practice rules, device performance, third-party technology dependencies and changes in reimbursement policy; and other risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
US Market News
1月前
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM ServicesMay 13, 2026 9:05 AM
ACCESS NewswireHighlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunities TAMPA, FL / ACCESS Newswire / May 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.com1 MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
US Market News
2月前
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient LivesApril 14, 2026 7:05 AM
ACCESS NewswireJoint venture executed combining Wellgistics Hub and KareRx Hub technology and operationsIntegrated platform accelerates pharmaceutical access, fulfillment, and commercializationCombined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical ‘lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical ‘lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.Wellgistics Media & Investor Contact
Media: media@wellgisticshealth.com
Investor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
US Market News
3月前
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric DisordersMarch 23, 2026 9:05 AM
ACCESS NewswireTAMPA, FL / ACCESS Newswire / March 23, 2026 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX) today announced that it has entered into a non-exclusive, non-binding Letter of Intent ("LOI") to evaluate a potential acquisition of Neuritek Therapeutics, a neuroscience-focused research organization.The proposed all stock transaction, if completed, is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business. Through its integrated ecosystem spanning prescription fulfillment, wholesale distribution, and AI-driven patient access solutions, Wellgistics connects manufacturers, providers, and a nationwide network of independent pharmacies. The Company believes that adding a research-focused organization could strengthen alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.The transaction remains subject to the completion of due diligence, negotiation and execution of definitive agreements, approval by the boards of directors of the respective parties, and other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated on the terms currently contemplated, or at all. The LOI is non-binding and does not obligate either party to complete the proposed transaction. The scope, structure, and terms of any potential transaction remain under evaluation and may change materially as a result of ongoing diligence and negotiations.The Company is also actively evaluating additional strategic opportunities across the healthcare and life science sectors as part of its broader growth strategy. These opportunities may include acquisitions, partnerships, or other strategic transactions. There can be no assurance that any such initiatives will result in completed transactions.About Wellgistics Health, IncWellgistics Health is a rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access. The Company has built an integrated, high-performance ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions, directly connecting pharmaceutical manufacturers, healthcare providers, and a nationwide network of independent pharmacies.By combining infrastructure, data, and intelligent automation, Wellgistics is executing on a capital-efficient model designed to capture significant share in large and fragmented healthcare markets. The Company is focused on expanding high-margin revenue streams, deepening strategic manufacturer relationships, and driving operating leverage across its platform. With a differentiated end-to-end offering and disciplined execution, Wellgistics is positioned to accelerate growth, enhance earnings visibility, and deliver outsized long-term value for shareholders.About Neuritek Therapeutics Inc.Neuritek Therapeutics Inc. has developed a next-generation bio-mechanism based treatment, treating the root cause of Post-Traumatic Stress Disorder (PTSD). Neuritek's first to market treatment is an orally active inhibitor of fatty acid amide hydrolase type 1 (FAAH1), the enzyme responsible for metabolizing anandamide (AEA) and the first mechanisms-based treatment for PTSD. The company was founded by Doctor William Hapworth MD., a pioneer in clinical research and a practicing psychiatrist with over 30 years' experience.Learn more at www.neuritek.com or join the conversation at LinkedIn, neuritek-therapeutics-incForward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other applicable federal securities laws. These forward-looking statements include, without limitation, statements regarding: the potential acquisition of Neuritek Therapeutics, Inc. ("Neuritek"), including the anticipated structure, valuation, timing, and likelihood of completion of any transaction; the preliminary and non-binding nature of the letter of intent; the potential strategic, operational, and financial benefits of any such transaction; the Company's ability to negotiate and enter into definitive agreements; the Company's ability to obtain any required financing; the integration of any acquired business; and the Company's broader growth strategy and future performance.Forward-looking statements may be identified by words such as "may," "could," "would," "should," "expect," "anticipate," "believe," "intend," "plan," "project," "estimate," "potential," "opportunity," "target," "forecast," "continue," "will," and similar expressions.These forward-looking statements are based on current expectations, assumptions, and estimates and are subject to significant risks and uncertainties, many of which are beyond the Company's control. Important factors that could cause actual results to differ materially include, but are not limited to: the risk that the parties do not enter into definitive agreements; the risk that the letter of intent is terminated or does not result in a completed transaction; uncertainties related to the preliminary nature of the proposed valuation and transaction terms, which may change materially; the risk that any required financing is not obtained on acceptable terms or at all; the risk that anticipated benefits of any transaction are not realized; risks associated with integrating a research-focused organization into the Company's existing business; risks related to the development, testing, regulatory approval, and commercialization of pharmaceutical or therapeutic products, including the possibility of unfavorable clinical results or delays; regulatory and compliance risks; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date they are made, and undue reliance should not be placed on such statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
US Market News
3月前
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per ShareMarch 19, 2026 8:05 AM
ACCESS NewswireTAMPA, FL / ACCESS Newswire / March 19, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President and Interim Chief Executive Officer, Prashant Patel, together with an additional participant from the Company's Board of Directors, entered into agreements with the Company to convert an aggregate of approximately $2.0 million of accrued compensation into shares of the Company's common stock at a conversion price of $0.20 per share, representing a premium to the Company's recent trading price. In connection with the conversion, the Company will issue approximately 10,000,000 shares of common stock.In addition, the Company issued an aggregate of 10,000,000 warrants to purchase shares of common stock at an exercise price of $0.01 per share (the "Warrants"), which were issued as additional consideration in connection with the conversion. The Warrants are exercisable immediately, have a term of 5 years from issuance, and are subject to customary anti-dilution adjustments.This conversion, which was approved by the disinterested directors of the Board, reflects Mr. Patel's confidence in the Company's strategic direction and his commitment to creating long-term shareholder value. Further reinforcing Mr. Patel's belief in the Company's long-term success, the newly issued shares of the Company's common stock are subject to a lock-up agreement restricting transfers for a period of 6 months, subject to customary exceptions.The structure of the transaction, including the issuance of Warrants, was designed to align management and director incentives with long-term shareholder value creation."I believe Wellgistics has the potential to build upon its vision and bring long lasting value to all healthcare stakeholders," said Mr. Patel. "This conversion reinforces my unwavering belief in our team, our mission, and the transformative impact we will have on the future of healthcare."About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the expected benefits of the debt conversion transaction, including its anticipated impact on the Company's balance sheet, liquidity, capitalization, and alignment of management and director interests with those of stockholders, as well as the Company's strategic plans, growth initiatives, and long-term value creation.In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology. These statements are based on current expectations, estimates, and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements.These risks and uncertainties include, without limitation, risks related to the Company's ability to realize the anticipated benefits of the debt conversion transaction; the potential dilutive impact of the issuance of common stock and warrants, including upon exercise of the warrants; the Company's ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the Company's stock price; the Company's ability to execute its business strategy and growth initiatives; and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share
US Market News
3月前
Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic DirectionMarch 13, 2026 9:00 AM
ACCESS NewswireTAMPA, FL / ACCESS Newswire / March 13, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that its President & Interim-CEO Prashant Patel, RPh released a letter to shareholders.The prescription drug and broader healthcare landscapes in the United States are rapidly changing. From the direct involvement of the federal government in providing discount cards for prescription drugs via to direct to consumers (DTC) online platform TrumpRx, to major pharmaceutical manufacturers offering prescription obesity drugs DTC through their own online pharmacies, to increasing percentages of patients receiving prescriptions for obesity and other drugs from physicians through telemedicine, it is clear that technology is rapidly changing how Americans engage with the healthcare system. This emerging shift in the healthcare market that gained significant momentum during the height of the COVID-19 pandemic has significant long-term consequences for independent pharmacies and providers throughout the country.Here at Wellgistics Health, we have been evaluating how best to leverage our pharmaceutical distribution businesses and deep healthcare relationships to position ourselves for the healthcare system tomorrow. After thorough review, we have determined that the best path forward for us is to transition our focus towards becoming a seller of prescription drugs and related services directly to patients via the Company's online pharmacy, and to leverage our relationships with independent pharmacies and other more local service providers to coordinate patient care with a view towards expanding the scope of our industry-leading EinsteinRx artificial intelligence hub platform to enable its use in areas beyond prescription drug dispensing optimization, towards optimization of patient outcomes.To this end, we have been strategically expanding marketing and healthcare technology relationships in preparation for this new direction. Our emerging partnership with NFL Alumni Health is set to provide us with access to a uniquely positioned group of influencers with unparalleled brand awareness and trust, capable of generating deep consumer engagement that we believe will help us elevate our new message to consumers throughout the United States in the second half of the year as football season kicks into gear. We have exclusively licensed technology from DataVault AI in preparation for the deployment of the Company's proprietary drug serialization solution PharmacyChain™ that will allow us not only to tokenize prescription drug data, but also data of each data aspect required for a prescription drug to be dispensed - which includes the aggregation of electronic patient records (EHD) data such as prior diagnoses, diagnostic testing results and other key data. We recently gained access to a proprietary lower-cost eligibility and benefits verification tool sufficiently attractive to compete for pharmacy and partner verification business in anticipation of the deployment of PharmacyChain so that there is an immediate incentive for partners to work with us as we begin to expand our healthcare ecosystem beyond pharmacy.We are also leveraging our deep understanding of pharmacy science to position ourselves on the side of patients with respect to mitigating the side effects of prescription drugs in rapidly growing and large underserved medical conditions. To this end, the Company's partnership with Tollo Health has positioned us to target two large chronic conditions that currently experience incomplete outcomes and/or side effects from currently approved prescription drug solutions with the over 36 million+ (12%+ of US population)[1] & growing diabetic and/or obese patients currently on GLP-1 medication via medical food Forzet™ and the over 18 million+ (6% of US population)[2] suffering from Long COVID via 3CL protease cleansing dietary supplement Tollovid™. Additionally, Tollo has natural medical food product Galectovid™ that is targeted towards the 6-10 annual viral infections each American (300 million+)[3] contracts, the vast majority of which are left untreated and have been increasingly linked to later-in-life chronic diseases such as cancer, Alzheimer's disease and multiple sclerosis.While we have made strides in this new direction, with the longer-term and medium terms outlook shaping up nicely, we are now preparing to focus on the immediate term execution phase that will position us to be able to complete this shift. To this end, we are actively preparing our telemedicine and diagnostic testing strategies, aiming to develop a closed-loop ecosystem that pharmaceutical manufacturing and other partners will be attracted to as a result of the marketing power, data generation and patient flow capabilities that will build value for their brands. We are also engaged with payers who have expressed a strong interest in being able to help shape our PharmacyChain solution to help solve key inefficiencies that currently plague the US healthcare system and result in higher costs with poor outcomes and expect to secure relationships that will allow us to begin to deploy our emerging solutions in a stepwise fashion, initially around mitigating GLP-1 related muscle loss.We strongly believe that now is the time to take these decisive actions so that we can retool our offering for the future. We intend to fortify our relationships with the Wellgistics Pharmacy Network by making available many more tools to help pharmacists manage their patients, and expect that as pharmacies are able to confidently expand their service offerings, we will be able to enable them with products and relationships they would otherwise not have access to alone, strengthening our value proposition to them via new revenue streams at a time of compressing margins and making them an extension of our own offering where appropriate.We believe in our mission, cognizant of the broader changes in the healthcare landscape and clear-eyed with respect to the challenges ahead.Thank you for taking the time to read this letter, for being a shareholder and for joining us in our journey to revolutionize healthcare in America.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet™, the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology.Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet™ is intended to diagnose, treat, cure, or prevent any disease.[1] https://www.statista.com/chart/35919/key-figures-usage-and-opinion-glp-1-medication-weight-loss-drugs-in-the-united-states/#:~:text=In%20mid/late%202025%2C%2012.4,surveyed%20in%202024%20and%202025.[2] https://www.hhs.gov/longcovid/index.html[3] https://pmc.ncbi.nlm.nih.gov/articles/PMC10116010/Wellgistics Media & Investor Contact:Media:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction
US Market News
3月前
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)March 9, 2026 7:40 AM
ACCESS NewswireGLP-1 agonist market expected to grow from $70B in 2025 to $201B in 20301Proprietary Forzet formulation provides pharmacists, physicians and patients with unique solution for GLP-1 drugs' primary side effectForzet targeting preservation of muscle while on GLP-1 agonist therapy to facilitate continued patient adherence and muscle redevelopment following therapy discontinuation to help mitigate weight regain TAMPA, FLORIDA / ACCESS Newswire / March 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics") , a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced the launch of medical food Forzet™ for the dietary management of muscle loss associated with weight loss therapies. Forzet is being launched initially to physicians and pharmacists who prescribe and dispense GLP-1 agonist drugs. Forzet's proprietary formulation has been evaluated in multiple controlled clinical studies, including in patients with Type 2 diabetes, heart failure and COPD in Europe. Forzet will initially be be made available through the Company's affiliated pharmacy and select members of the Wellgistics Pharmacy Network. Forzet is classified as a medical food intended for the dietary management of muscle loss associated with weight loss therapies under physician supervision. Forzet is not an FDA-approved drug, is available over the counter and does not require a prescription. "Forzet is indicated for the dietary management of muscle loss associated with weight loss therapies," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "GLP-1 agonist drugs such as Ozempic®, Wegovy®, Mounjaro® and others are members of the fastest growing class of drugs worldwide because of myriad benefits that result from losing weight. While the benefits of the weight loss associated with GLP-1 agonist therapy can no longer be denied, it remains the case that a significant amount of that weight loss comes from loss of muscle. As such, the Company believes there may be a significant market opportunity for a medical food product that distinguishes itself from dietary supplements by virtue of its extensive clinical data package in sarcopenia associated with other muscle loss-related medical conditions and -stringent cGMP manufacturing requirements."Mr. Patel continued, "We intend to leverage Forzet's unique value proposition by recommending it as an adjunct solution for patients prescribed GLP-1 agonist drugs via pop-ups through our EinsteinRx hub technology at the point-of-sale in Wellgistics Pharmacy Network pharmacies. Additionally, as we build out our own telehealth customer base where we can more fully service patients through our own Wellgistics Pharmacy both in-store and online, we intend to make GLP-1 drug and related solutions such as Forzet a central feature of our direct-to-consumer (DTC) offering in order to drive loyalty by way of unique product offering as we begin to expand our DTC efforts.""My practice primarily addresses patients seeking weight loss therapies," said Dr. Vivek Bansal, MD MPH, Triple Board-Certified Endocrinologist and Founder of The EnLyv Clinics in Bridgewater, NJ. "We have been working through myriad products seeking to address muscle loss while on current weight loss therapies, and believe Forzet represents a unique solution that has worked well in other sarcopenia-related medical conditions. We are excited to make this available to our patients."Dr. Bansal is an independent physician and has not been compensated by Wellgistics for this statement.The GLP-1 agonist market is expected to grow from $70 billion in 2025 to $201 billion in 2030 1 according to Grandview Research. The market growth is driven by drugs with increasing potency to induce weight loss, more convenient oral formulations that help drive adoption as well as increasing interest from non-obese patients looking for weight loss alternatives to diet & exercise. Limiting factors for the expansion of the GLP-1 market include side effects such as muscle loss and gastrointestinal challenges.Ozempic ®, Wegovy ®, and Mounjaro ® are registered trademarks of their respective owners. Wellgistics Health, Inc. is not affiliated with or endorsed by the manufacturers of these products.About FORZET ™[2]Product Description: Medical Food for the dietary management of muscle loss associated with weight loss therapies.Classification: "Food for Special Medical Purposes" in accordance with section 5 (b) of the Orphan Drug Act (21 U.S.C. 360ee (b) (3). Nutritional requirement caused by a specific medical condition. For use under medical supervision.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx ™ into its patented blockchain-enabled smart contracts platform PharmacyChain ™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the Company's future financial or operating performance and may include, without limitation, statements regarding the anticipated launch, availability, distribution, commercialization and potential adoption of Forzet ™, the expected benefits of the product, the Company's plans to integrate Forzet into its pharmacy network and telehealth offerings, the development and expansion of the Company's direct-to-consumer initiatives, and the potential growth of the GLP-1 agonist market. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," "continue," or the negative of these terms or other comparable terminology.Forward-looking statements are based on current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among other things, risks related to the commercialization and market acceptance of the Company's products and services, the Company's ability to successfully expand its pharmacy network and telehealth initiatives, regulatory and compliance considerations relating to medical foods and healthcare products, competition in the healthcare and pharmaceutical distribution markets, changes in market conditions, and other risks and uncertainties described from time to time in the Company's filings with the U.S. Securities and Exchange Commission.Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. The Company makes no representation that Forzet™ is intended to diagnose, treat, cure, or prevent any disease.Wellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.com1 https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market
2 https://tollohealth.com/forzet/SOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
US Market News
4月前
Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization MandateMarch 5, 2026 7:40 AM
ACCESS NewswireHyperledger Fabric, Ethereum/Polygon, VeChain, Quorum /Besu and Corda (R3) selected as most suitable blockchain platforms to build PharmacyChain™U.S. prescription drugs market project to grow from $634 billion market to $883 billion by 2030 according to Grandview Research[1]Global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, according to Grandview Research[2] TAMPA, FLORIDA / ACCESS Newswire / March 5, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (AI) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has completed its evaluation process to select the most suitable blockchain platforms on which to build smart contracts-enabled pharmaceutical drug tracking system PharmacyChain that will further enable industry-wide serialization mandates, such as the United States' Drug Supply Chain Security Act (DSCSA[3]). The Company selected Hyperledger Fabric, Ethereum/Polygon, VeChain, Quorum/Besu and Corda (R3) as the most suitable blockchain platforms currently in use in order to initiate PharmacyChain development. The Company is seeking to complete the development work needed to establish closed-loop, HIPAA-compliant data transfers required to complete smart contracts within its own Wellgistics Pharmacy by the end of the second quarter of 2026."Now that we have identified what we believe are the best technologies currently available upon which to build PharmacyChain, we are beginning the development work needed to make it operational initially within our own pharmacy by the end of next quarter," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "While we intend for PharmacyChain to be made available for our own pharmacy and the 6,500+ independent pharmacies within the Wellgistics Pharmacy Network later this year, we also believe that other major pharmacy industry participants may increasingly adopt similar solutions given our strong intellectual property position. We intend to build multiple PharmacyChain options on different blockchain platforms such that large manufacturers, wholesalers and pharmacies will be incentivized to work with us in order to gain access to our patented technology to help them improve their pharmaceutical supply chain management systems, delivering on our promise of building the ‘Health Data Railroad' through tokenization and smart contracts. We intend to program PharmacyChain in such a way that other key aspects of the healthcare ecosystem will be able to seamlessly integrate their data in order to produce a best-in-class product for all key healthcare stakeholders."Wellgistics' intellectual property, exclusively licensed from Datavault AI, creates a competitive advantage related to the use of smart contracts in the $4.9 trillion US healthcare market[4]. PwC estimates $1 trillion opportunity to shift healthcare spending[5] towards a digital-first, proactive, and personalized system of care that minimizes administrative burden. The global blockchain in healthcare market currently stands at $11 billion, and is projected to grow to $214 billion by 2030 according to Grandview Research, with compound annual rates expected to exceed 60% per year. The U.S. prescription drug market, where independent pharmacies play a vital role, represents a $634 billion market opportunity, projected to grow to $883 billion by 2030 according to Grandview Research. The global healthcare as a service market is expected to grow from $25 billion in 2024 to $74 billion by 2030 according to Grandview Research[6] amid increasing adoption of cloud-based solutions across hospitals, clinics and insurance companies. Blockchain-based, tokenized smart contracts technology integration leveraging artificial intelligence will help significantly improve transparency in healthcare, delivering trust and efficiency while improving patient outcomes.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the development, implementation, and potential adoption of the Company's PharmacyChain™ platform, anticipated benefits of blockchain and artificial intelligence technologies in healthcare, expected development timelines, and potential market opportunities. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, among others, risks related to technology development and implementation, commercial adoption of the Company's solutions, regulatory developments, protection of intellectual property, and general market conditions, as well as other risks described in the Company's filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date of this press release, and the Company undertakes no obligation to update them except as required by law.Wellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.com[1]https://www.grandviewresearch.com/industry-analysis/us-pharmaceuticals-market-report[2]https://www.grandviewresearch.com/industry-analysis/blockchain-technology-healthcare-market[3]https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa[4]https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet#:~:text=Historical%20NHE%2C%202023:,the%207.8%25%20growth%20in%202022[5]https://www.pwc.com/us/en/industries/health-industries/library/future-of-health.html[6]https://www.grandviewresearch.com/industry-analysis/healthcare-software-as-a-service-market-reportSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate
US Market News
4月前
DataVault AI and Wellgistics Health Announce Plans to Expand Partnership to Include Healthcare Delivery Intellectual Property for Healthcare as a Service (HaaS) Blockchain-enabled Smart ContractsFebruary 23, 2026 8:30 AM
ACCESS NewswireThe global blockchain in healthcare market is projected to grow from $11 billion in 2024 to $214 billion by 2030, with annual growth rates expected to exceed 60%Ongoing PharmacyChain® technology build-out already involves key technology components necessary to enable Healthcare as a Service (HaaS) smart contractsDatavault AI partner programming capabilities included to speed market entryWellgistics' recently announced NFL Alumni Health partnership provides trusted marketing capability to help drive market awareness and adoptionWellgistics Pharmacy's online prescription fulfillment capability set to become primary distribution channel for prescription drugs and OTC health productsWellgistics Pharmacy Network participants to enable 'hub and spoke' model for in-person healthcare touchpoints for patients and local providers via referral networkWellgistics plans to update its current iOS app as the vehicle to enable adoption PHILADELPHIA, PA AND TAMPA, FL / ACCESS Newswire / February 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT)("Datavault AI"), a provider of data monetization, credentialing, digital engagement, and real-world asset tokenization technologies, and Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics"), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced plans to expand their existing blockchain-enabled smart contracts partnership initially focused on digitizing tracking of prescription drugs from script to fulfillment. The companies intend to add additional Datavault AI intellectual property that will enable Wellgistics' emerging Healthcare as a Service (‘HaaS') business model that will include data integration from hospitals, clinics, diagnostics labs, mental health AI tools, wearables and insurance companies in order to deliver a comprehensive healthcare solution designed to improve patient outcomes while reducing total cost of care."Our recently announced partnership with NFL Alumni Health allows us to have confidence that we have a trusted partner capable of reaching and motivating patients to take greater control over their healthcare with HaaS," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "With the emergence of telehealth as fixture in the healthcare system, and all key constituents within healthcare increasing adopting cloud-based solutions to help integrate data transfer, it makes perfect sense to target a comprehensive app-based solution that integrates various' provider data outputs for patients to take control of their healthcare. Datavault AI's unique smart contracts intellectual property positions us to have a protected first mover advantage for our proprietary app through which patients will be able to securely consolide all of the key HaaS data needed in order to train our AI models with a view towards improving patients outcomes with a lower total cost of care."Wellgistics intends to deploy a ‘hub and spoke' prescription drug delivery model relying primarily on its own online Wellgistics Pharmacy in the United States to dispense prescription drug and OTC products to patients, while facilitating patient engagement with local independent pharmacies within the Wellgistics Pharmacy Network for urgent fulfilment and for more complex healthcare interactions, including a local referral network for non-prescription drug-related healthcare services. The Company is leveraging its partnership with Tollo Health to enable telemedicine visits initially targeting the GLP-1 and Long COVID markets, as well as a patient engagement tool via a stealth mental health AI startup in which Wellgistics recently made a strategic investment . Wellgistics intends to continue to expand its ecosystem to include hospitals, clinics, diagnostic labs, as well as other healthcare and wellness service providers to make available the best solution for patients. Wellgistics plans to update its current iOS app as the patient adoption mechanism."Datavault AI is focused on the creation of shareholder value with and for our partners through strategic field of use licensing. We believe our license and royalty agreement with Wellgistic allows us together to solve for pharmaceutical logistics issues, using blockchain and AI, that have plagued the healthcare industry for far too long," said Nathaniel Bradley, President & CEO of Datavault AI. "We intend to work very closely with Wellgistics' management, while making available our patented solutions that will have Wellgistics prepared for the leap to quantum computing and as an immutable future in this all important market of healthcare."The global blockchain in healthcare market currently stands at $11 billion USD, and is projected to grow to $214 billion by 2030 according to Grandview Research, with compound annual rates expected to exceed 60% per year. The U.S. prescription drug market, where independent pharmacies play a vital role, represents a $634 billion market opportunity, projected to grow to $883 billion by 2030 according to Grandview Research. The global healthcare as a service market is expected to grow from $25 billion in 2024 to $74 billion by 2030 according to Grandview Research amid increasing adoption of cloud-based solutions across hospitals, clinics and insurance companies. The global diagnostics services market was estimated at $1.1 trillion in 2024 and is expected to grow to $4 trillion by 2034 according to Polaris market research. The healthcare wearables medical device market is expected to grow from $42 billion in 2024 to $160 billion by 2030 according to Grandview Research, driven largely by the rise of remote patient monitoring, home healthcare, and a greater emphasis on fitness and healthy living. The implanted medical device market was $91 billion in 2023 and is expected to grow to $130 billion by 2030 according to Grandview Research. These markets all continue to face supply chain inefficiencies, lack of transparency, fraud, waste, abuse and delayed payments that strain profitability and patient care. Blockchain-based, tokenized smart contracts technology integration leveraging artificial intelligence could help significantly improve healthcare transparency, trust and efficiency while improving patient outcomes.These healthcare markets are expected to be significantly disrupted by technology adoption in the coming years as the need for secure data transfer and AI analysis necessitates access to blockchain-enabled solutions that address the pending quantum computing paradigm shift. Wellgistics and Datavault AI believe they are well positioned to take advantage of these market shifts."We are very excited with the direction of our Datavault AI partnership given their unique intellectual property as it relates to smart contracts, digital twins and data valuation in healthcare," said Srini Kalla, Chief Technology Officer at Wellgistics. "Having previously served in senior roles at OptumRx (NYSE: UNH) and Elevance Health (NYSE: ELV), I am excited to be here at Wellgistics as we begin the smart contracts revolution in healthcare with a proprietary intellectual property position."DataVault AI's industry-leading platform, including its patented Information Data Exchange® (IDE) and expertise in securely attaching physical assets to immutable blockchain metadata, provide the foundational intellectual property that enables this tokenization. By leveraging DataVault AI's robust, regulatory-compliant technology, Wellgistics can create tokenized digital representations of healthcare-related elements - from patient profiles to diagnostic lab results to prescription fulfillment - facilitating seamless smart contract execution, real-time data integrity, reduced intermediaries, and new avenues for efficient, trustless, quantum-proof healthcare transactions.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.About Datavault AIDatavault AI™ (NASDAQ:DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. Datavault AI is an IBM Platinum Partner. The Company's cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI's Acoustic Science Division features WiSA®, ADIO® and Sumerian ® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange ® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI's technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.Forward-Looking StatementsThis press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. ("Datavault AI," the "Company," "us," "our," or "we") and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as "may," "might," "will," "shall," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," "goal," "objective," "seeks," "likely" or "continue" or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the timing, scope and expected benefits of Datavault AI's audience engagement activities and outreach, and the anticipated benefits of Datavault AI's commercial partnerships and/or collaborations, including, without limitation, with Sports Illustrated, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein.Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks related to the ability of Datavault AI to successfully implement its commercial partnerships, collaborations and/or strategies; changes in market demand for Datavault AI's services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC's website at www.sec.gov, and could cause actual results to vary from expectations.The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI's forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.Trademarks, Trade Names, Service Marks and CopyrightsWe own or have rights to use various trademarks, tradenames, service marks and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the ©, ®, and symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties' trademarks, tradenames, service marks or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.Media Contact:ir@dvlt.aiWellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: DataVault AI and Wellgistics Health Announce Plans to Expand Partnership to Include Healthcare Delivery Intellectual Property for Healthcare as a Service (HaaS) Blockchain-enabled Smart Contracts
US Market News
4月前
Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI StartupFebruary 18, 2026 7:40 AM
ACCESS NewswirePreviously announced partnership with Tollo Health subsidiary TolloCare adding telehealth service offering to drive Wellgistics Pharmacy prescription drug dispending of GLP-1 drugs and promote patient engagement via mental health AI software solution for compliance and to promote lifestyle changes TAMPA, FL / ACCESS Newswire / February 18, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has completed a strategic investment in a San Francisco-based mental health AI startup on the cusp of launching its service following successful beta testing. The investment fortifies the Company's strategic partnership with Tollo Health that was expanded to support Wellgistics' partnership with NFL Alumni Health.Wellgistics is increasing its focus on patient engagement to help improve prescription drug compliance, promote complementary healthcare products such as medical food Forzet® that helps improve muscle maintenance via mitochondrial biogenesis, as well as further entrench itself within its Wellgistics Pharmacy Network as local pharmacy outlets become touchpoints to provide additional products, services and support for patients. By combining digital engagement with local physical pharmacy outlets, Wellgistics aims to provide unique support for patients throughout their healthcare journey, especially patients who are initiating GLP-1 drug treatment and need assistance managing potential side effects.According to SNS Insider, the mental health software is expected to grow from $6.3 billion in 2025 to $18.1 billion by 2033 driven by the growing adoption of digital healthcare platforms, increasing awareness of mental health conditions and the increasing adoption of software-based treatments, monitoring, and care coordination in clinical and non-clinical settings.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s filings with the SEC. Forward-looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.Wellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI Startup
US Market News
4月前
NFL Alumni Health Partners with Wellgistics Health to Deploy Technology to Improve Health Outcomes for Former NFL Players and Rural CommunitiesFebruary 9, 2026 8:30 AM
ACCESS NewswireWellgistics Health to leverage EinsteinRx™ AI pharmacy hub and PharmacyChain™ smart contracts to drive healthcare optimization for former NFL players that and rural communitiesFocus areas include mental health, weight loss, sleep apnea, cardiometabolic disease, pain management and Long COVIDNFL Alumni Health Ambassadors to help support Wellgistics' healthcare access and ease-of-use message to rural communities though Wellgistics' pharmacy and independent pharmacy networkWellgistics and NLF Alumni Health management attended 'Radio Row' during week of Super Bowl LX in San Francisco TAMPA, FLORIDA / ACCESS Newswire / February 9, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI') platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has entered into an agreement with NFL Alumni Health to establish healthcare and wellness programs that expand access to healthcare and wellness services, improve cost transparency and drive patient outcomes. The programs will initially be developed and optimized for former NFL players and thereafter will be deployed more broadly in rural communities leveraging Wellgistics' network of 6,500 independent pharmacy network (the ‘Wellgistics Pharmacy Network'). The partnership will initially focus on improving key health priorities including mental health, weight loss, sleep apnea, cardiometabolic disease, pain management and Long COVID."The healthcare technological advancements being developed by Wellgistics Health strike at the core of the inefficiencies involved in delivering optimal care for former NFL players, as well as the broader rural communities in the United States," stated Billy Davis, a two-time Super Bowl champion with the Dallas Cowboys and Baltimore Ravens, and co-director of NFL Alumni Health. "By leveraging AI to ensure that physcians make the best prescribing decisions, medications are efficiently delivered to patients, proper support is made available to improve outcomes and smart contracts provide the oversight so that no detail is missing to ensure timely coordindation of benefits and payments, Wellgistics' integrated solution represents the future of healthcare. We intend to provide our alumni with best in breed healthcare, and Wellgistics is helping to make that easier.""We are excited to partner with NFL Alumni Health as our first ‘white glove' client around whom we intend to optimize EinsteinRx and PharmacyChain to deliver the best healthcare experience for organizations," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "We have been making good progress with the integration of our point-of-sale EinsteinRx tool into Wellgistics Pharmacy Network pharmacies, and this now allows us to actually start developing new business for organizations because we can appropriately route prescriptions to locations that offer our full suite of services. As we expand this capability throughout the country, we are delighted that NFL Alumni Health has agreed to get their Ambassadors to help spread the message as a trusted voice from the local community to encourage people to engage more directly with their local pharmacies to improve health outcomes for themselves, their families and their local communities."About NFL Alumni HealthNFL Alumni Health is a nonprofit organization dedicated to improving the health and wellness of former professional football players, their families and the communities they serve. Through advocacy, education and partnerships with leading healthcare organizations, NFL Alumni Health addresses critical public health issues and promotes innovative solutions that enhance well-being. By leveraging the influence of NFL legends, the organization fosters impactful community engagement initiatives, including health screenings, educational symposiums and national awareness campaigns. For more information, visit nflalumnihealth.org.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.For more information, visit www.wellgisticshealth.com.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in Wellgistics Health, Inc.'s filings with the SEC. Forward-looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.Wellgistics Media & Investor ContactMedia:
media@wellgisticshealth.comInvestor Relations:
IR@wellgisticshealth.comSOURCE: Wellgistics Health, Inc.View the original press release on ACCESS NewswireOriginal: NFL Alumni Health Partners with Wellgistics Health to Deploy Technology to Improve Health Outcomes for Former NFL Players and Rural Communities
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
georgie18
3週前
glenn1919
4週前
chumfm
1月前
81vette
5月前
メールアドレスで登録
